Resources

Year: 2015

Remy Corvese,
Senior Analyst, Zitter Health Insights

Since their development in the late 1980s, Statins have remained the gold standard in treating and regulating cholesterol production. Blockbuster drugs such as Lipitor (atorvastatin) and Crestor (rosuvastatin) produced annual revenues of over $12B globally in the mid-2000s. However, this blog post will discuss the emergence of a unique alternative treatment in lowering LDL cholesterol […]

Larisa Vulakh,
Senior Analyst, Zitter Health Insights

The psoriasis marketplace has grown significantly in the last couple of years with newer agents being approved. With a new set of biologics entering the market, psoriasis is quickly becoming a dynamic therapeutic area. The newest entrant into the psoriasis market, Novartis’ Cosentyx, was approved in January 2015. By targeting IL-7, Cosentyx’s unique mechanism of […]

ZHI,
Zitter Health Insights

As a part of Zitter Health Insights’ ongoing commitment to continuously improving its products, ZHI has expanded the covered lives granularity and is including more timely updates for greater accuracy. This lives enhancement also includes more detailed PBM information and is a value added service to our well regarded and widely accepted Policy & Access Tracking Tool.